Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Lantern Pharma Inc
LTRN
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.6684
0.0016
0.24%
Dern. MÀJ: Oct 16, 6:34 PM
$0.6471
-0.0197
-2.96%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Lantern Pharma Financials
Lantern Pharma (LTRN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.38) by 50 percent. This is a 42.5 percent decrease over losses of $(0.40) per share from the
Benzinga Newsdesk
PRO
Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 28.57 percent increase over losses of $(0.42) per share from
Benzinga Newsdesk
Earnings Scheduled For May 15, 2026
Benzinga Insights
PRO
Lantern Pharma Q4 EPS $(0.36) Beats $(0.46) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21.74 percent. This is a 33.33 percent increase over losses of $(0.54) per share from
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
PRO
Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the
Benzinga Newsdesk
